Exelixis Initiates COMET-1 Pivotal Trial Focused on Overall Survival in Men With Advanced Prostate Cancer
06:01 EDT 30 May 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
Exelixis, Inc. (NASDAQ:EXEL) today announced the initiation of COMET-1,
a phase 3 pivotal trial of cabozantinib in men with metastatic
castration-resistant prostate cancer (mCRPC). The primary endpoint for
COMET-1 is overall sur...
Other Sources for this Article
Exelixis, Inc.
Charles Butler, 650-837-7277
Vice President,
Investor
Relations and
Corporate Communications
cbutler@exelixis.com
More From BioPortfolio on "Exelixis Initiates COMET-1 Pivotal Trial Focused on Overall Survival in Men With Advanced Prostate Cancer"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
